Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
about
Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivinLatent bone metastasis in breast cancer tied to Src-dependent survival signalsThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceModeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine dataMechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.Signaling responses after exposure to 5 alpha-dihydrotestosterone or 17 beta-estradiol in norepinephrine-induced hypertrophy of neonatal rat ventricular myocytesInhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell linesAndrogen-induced cell migration: role of androgen receptor/filamin A association17β-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin.Elevated c-Src and c-Yes expression in malignant skin cancersSubcellular localization of total and activated Src kinase in African American and Caucasian breast cancerSrc family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinaseβ1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivityFocal adhesion kinase: a promising target for anticancer therapy.Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.Luminal breast cancer metastasis is dependent on estrogen signaling.Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cellsThe dual kinase complex FAK-Src as a promising therapeutic target in cancerTargeting tyrosine kinases and autophagy in prostate cancer.Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.Targeting focal adhesion kinase in fibrotic diseases.The regulatory roles of phosphatases in cancer.Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.c-Src regulates cell cycle proteins expression through protein kinase B/glycogen synthase kinase 3 beta and extracellular signal-regulated kinases 1/2 pathways in MCF-7 cells.SRC increases MYC mRNA expression in ER+ breast cancer via mRNA stabilization and inhibition of p53 function.Sex steroids and breast cancer metastasis.YAP/TAZ Activation as a Target for Treating Metastatic Cancer.
P2860
Q21195209-D9183EE4-5E93-4983-881B-A3057032A310Q24648828-3C481372-DA1C-4E6A-BD88-8E2093F2D972Q28076745-529C460F-1F73-42C5-906E-B6F7D983B0BCQ28469088-9B6B507A-D5A4-4B47-AE03-2E8C85C7F101Q30441321-9E6E9DFB-C824-409A-8220-372E0B7FD2A6Q30666838-BB7EF09B-5678-4875-BDF6-5F84CA1CBFAAQ33637191-74D0CDCE-5DFF-4988-9CA3-E1640B8F3504Q33727986-F16E5239-3E65-4020-8C0E-E62BB3AF28DCQ33768039-BCE745E8-853C-4052-A1F0-3ECA33E5B357Q33831959-2B47C7DE-EE28-4A6F-9DE8-39A10EC1CAC5Q33983217-5887E396-3EFE-4E67-825C-9B3612D07701Q34114252-EB053077-6545-49A9-BAAA-FCEE9A8EADD0Q34211720-8AF6D5A6-F0DC-425B-85B8-8587FF3782B7Q34959208-215142D9-2349-4FC7-9179-C75D29DC5686Q34994336-A1B04769-3BDD-468D-9956-AA1E12D273BEQ35094072-A164E107-9C73-4633-95C0-00D6E5682D7EQ35608736-DBC7DCE9-AA68-4493-AF20-2EE0E7471F06Q35832949-89FB4B4F-790E-4EBA-AD6F-C2B193C713B8Q36263003-78899558-0549-402B-9AEA-6795DE080D07Q36612010-FB5E0A50-34BA-49BB-A9B8-3C2557DBEF1FQ36956729-3907C181-1865-4722-AC28-EC3DC94466CAQ37010584-C1DBD82B-3533-4A87-BD98-176D0CA814B0Q37276323-F5DFFF6A-072A-4D7F-93DC-E3CC8C900CFCQ37565394-BFC31077-43D3-40F2-8A05-4E4F6ABF8261Q37771259-023CAE4B-A9EC-49C1-8BAE-D47507441FBBQ37847052-31CE4504-DD39-4318-B5E5-2808116E0D55Q37992693-FB4CBF26-3470-4C22-A374-2FB4D9FD454AQ38074882-F29725E1-79BA-4D7A-8CEA-51610C268E9BQ38090432-2A252602-86A2-4B81-A9E1-DD7FEA46B6F1Q39479158-C2DC9B57-B1E0-4849-885D-8849F282329DQ39720714-E0C2F97D-B09D-4F17-8F88-D8C2A4EFC185Q40262820-B0BD9ADE-3DB9-429C-A8AB-2EC86E2C23EDQ43874359-F0FDB2A0-0869-464A-9F7C-815733CAF3C4Q47230860-E8BB162D-0BCC-4CBE-9F97-C26707FB8087Q53292930-FAD6E99C-415B-403C-92AF-3E830CBC6641Q54977387-27A8B16B-9D83-499A-BC1A-7E9C2FE5C894
P2860
Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Role of c-Src and focal adhesi ...... ceptor-positive breast cancer.
@en
type
label
Role of c-Src and focal adhesi ...... ceptor-positive breast cancer.
@en
prefLabel
Role of c-Src and focal adhesi ...... ceptor-positive breast cancer.
@en
P2093
P1476
Role of c-Src and focal adhesi ...... ceptor-positive breast cancer.
@en
P2093
J Stanley Smith
Maricarmen D Planas-Silva
Richard D Bruggeman
Ronald T Grenko
P356
10.1016/J.BBRC.2005.12.164
P577
2006-01-06T00:00:00Z